Structure Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 63.00K shares, a 7.35% decline year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 166.00K shares, a 50.60% decline year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 427.00K shares, a 527.94% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 635.00K shares, a 2342.31% increase year-over-year.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.29M shares, a 159.24% increase from fiscal 2023.
- Structure Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 498.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-12-31 | 63.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 1.29M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 166.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.30M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 427.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 1.47M shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 635.00K shares 10-Q · filed 2024-05-09 | 1.11M shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 68.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | 498.00K shares 10-K · filed 2024-03-08 |
| 2023-09-30 | 336.00K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | |
| 2023-06-30 | 68.00K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | |
| 2023-03-31 | 26.00K shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |